1 study found for:    12814712 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
Conditions: Cardiovascular Disease;   Cardiovascular Outcomes;   Kidney Transplant Recipients;   Kidney Transplantation
Interventions: Drug: Myfortic®;   Drug: Neoral®;   Drug: Cellcept®;   Drug: Prednisone

Indicates status has not been verified in more than two years